ReNerve Limited (ASX:RNV)

ReNerve Income Statement

Financials in millions AUD. Fiscal year is July - June.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Dec 31, 2025	Jun 30, 2025	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022
Revenue	0.33	0.27	0.18	0.13	-
Revenue Growth (YoY)	38.11%	53.18%	38.04%	-	-
Cost of Revenue	0.14	0.03	0	-	-
Gross Profit	0.19	0.24	0.18	0.13	-
Selling, General & Admin	3.4	2.95	2.22	1.88	1.27
Research & Development	1.4	1	0.77	0.3	1.04
Other Operating Expenses	0.14	0.14	-	-	-
Operating Expenses	5.4	4.7	3.29	2.32	2.33
Operating Income	-5.22	-4.45	-3.12	-2.2	-2.33
Interest Expense	-0.25	-0.25	-0.29	-0.01	-0
Interest & Investment Income	0.16	0.14	0.04	-	-
Other Non Operating Income (Expenses)	0.7	0.83	0.38	0.4	0.58
Pretax Income	-4.61	-3.73	-2.98	-1.8	-1.76
Net Income	-4.61	-3.73	-2.98	-1.8	-1.76
Net Income to Common	-4.61	-3.73	-2.98	-1.8	-1.76
Shares Outstanding (Basic)	144	123	95	-	-
Shares Outstanding (Diluted)	144	123	95	-	-
Shares Change (YoY)	44.82%	30.31%	-	-	-
EPS (Basic)	-0.03	-0.03	-0.03	-	-
EPS (Diluted)	-0.03	-0.03	-0.03	-	-
Free Cash Flow	-4.49	-3.03	-2.3	-1.51	-1.98
Free Cash Flow Per Share	-0.03	-0.03	-0.02	-	-
Gross Margin	56.49%	90.05%	99.65%	100.00%	-
Operating Margin	-1565.56%	-1639.23%	-1756.95%	-1709.17%	-
Profit Margin	-1382.55%	-1374.24%	-1682.86%	-1403.39%	-
Free Cash Flow Margin	-1347.94%	-1116.05%	-1295.48%	-1178.24%	-
EBITDA	-5.18	-4.41	-2.97	-2.05	-2.31
D&A For EBITDA	0.03	0.05	0.15	0.15	0.02
EBIT	-5.22	-4.45	-3.12	-2.2	-2.33

Source: S&P Global Market Intelligence. Standard template. Financial Sources.